Citius Pharmaceuticals Inc

CTXR05 Dec 2024
Healthcare
$3.48
+0.03 (+2.54%)
Lowest Today
$3.15
Highest Today
$3.75
Today’s Open
$3.48
Prev. Close
$3.55
52 Week High
$26.75
52 Week Low
$2.55
To Invest in Citius Pharmaceuticals Inc

Citius Pharmaceuticals Inc

Healthcare
CTXR05 Dec 2024
+0.03 (+2.54%)
1M
3M
6M
1Y
5Y
Low
$3.15
Day’s Range
High
$3.75
3.15
52 Week Low
$2.55
52-Week Range
52 Week High
$26.75
2.55
1 Day
-
1 Week
+10.3%
1 month return
+935.26%
3 month return
+574.07%
6 month return
+472.59%
1 Year return
+355%
3 Years return
+123.31%
5 Years return
+657.38%
10 Years return
-
Institutional Holdings
Armistice Capital, LLC
3.77
Vanguard Group Inc
3.33
Vanguard Total Stock Mkt Idx Inv
2.14
Vanguard Institutional Extnd Mkt Idx Tr
1.01
Geode Capital Management, LLC
0.97
BlackRock Inc
0.93
Millennium Management LLC
0.6

Market Status

Fundamentals
Market Cap
87.15 mln
PB Ratio
0.32
PE Ratio
0
Enterprise Value
7.29 mln
Total Assets
103.61 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA approved product, is a targeted immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma. Its late-stage pipeline includes Mino-Lok, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections; and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. The Pivotal Phase 3 Trial for Mino-Lok and a Phase 2b trial for Halo-Lido completed. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
Organisation
Citius Pharmaceuticals Inc
Employees
22
Industry
Biotechnology
CEO
Mr. Leonard L. Mazur
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities